INCY 25 (Jakafi 25 mg)
Generic Name: ruxolitinib
Pill imprint INCY 25 has been identified as Jakafi 25 mg.
Jakafi is used in the treatment of myelofibrosis; polycythemia vera; myeloproliferative disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 25 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- ruxolitinib
- Imprint:
- INCY 25
- Strength:
- 25 mg
- Color:
- White
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Multikinase inhibitors
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Incyte Corporation
More about Jakafi (ruxolitinib)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 2 Reviews – Add your own review/rating
- Drug class: multikinase inhibitors
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
